Please login to the form below

Not currently logged in
Email:
Password:

Sue Mahony to retire as president of Lilly Oncology

She will continue in her position until August 31

Eli LillyEli Lilly’s senior vice president and president of Lilly Oncology, Sue Mahony, is set to retire at the end of August after 18 years of service with the company.

Mahony led Lilly Oncology through the integration of ImClone and launched several brands including Verzenio.

She also most recently led the refocusing of the company’s oncology R&D strategy.

Prior to this, as senior vice president of human resources and diversity, Mahony played in a role in restructuring the company into business units.

She said: “What I’ve appreciated over the years is the opportunity to participate in something greater than myself.

“We make medicines that help patients with cancer live longer and what a privilege it’s been to wake up each morning with that as my life’s work.”

Prior to her time with Eli Lilly, Mahony has served in various roles for Amgen, Bristol-Myers Squibb and Schering-Plough.

Lilly has said it is considering internal and external candidates to find Mahony’s successor.

5th June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics